Dosing & Uses
AdultPediatric
Fibrodysplasia Ossificans Progressiva
Pending FDA approval for prevention of for prevention of heterotopic ossification (ie, new bone formation outside of the normal skeletal system) associated with fibrodysplasia ossificans progressiva (FOP)
Fibrodysplasia Ossificans Progressiva
Pending FDA approval for prevention of for prevention of heterotopic ossification (ie, new bone formation outside of the normal skeletal system) associated with fibrodysplasia ossificans progressiva (FOP) in females aged ≥8 years or males ≥10 years
Next:
Pharmacology
Mechanism of Action
Selective retinoic-acid receptor gamma (RARγ) agonist for prevention of heterotopic ossification (ie, new bone formation outside of the normal skeletal system) associated with fibrodysplasia ossificans progressiva
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
